Cargando…
Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
Randomized clinical trials with statins and other lipid-lowering drugs have shown the presence of a “residual cardiovascular risk” in those treated to “target” for LDL-cholesterol. This risk is mainly associated to lipid components other than LDL and in particular to remnant cholesterol (RC) and to...
Autores principales: | Baratta, Francesco, Cocomello, Nicholas, Coronati, Mattia, Ferro, Domenico, Pastori, Daniele, Angelico, Francesco, Ben, Maria Del |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002331/ https://www.ncbi.nlm.nih.gov/pubmed/36901696 http://dx.doi.org/10.3390/ijms24054268 |
Ejemplares similares
-
Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease
por: Pastori, Daniele, et al.
Publicado: (2018) -
Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study
por: Baratta, Francesco, et al.
Publicado: (2021) -
Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review
por: Coronati, Mattia, et al.
Publicado: (2022) -
Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease
por: Heo, Ji Hye, et al.
Publicado: (2023) -
New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress
por: Ferro, Domenico, et al.
Publicado: (2020)